Low PAPP-A and Pre-eclampsia Risk
Women with low first-trimester PAPP-A (<0.4 MoM) should be started on low-dose aspirin (81 mg daily) between 12-16 weeks of gestation and continued until delivery, as they face significantly increased risk of developing pre-eclampsia, particularly early-onset disease.
Risk Stratification
Low PAPP-A levels in the first trimester are strongly associated with pre-eclampsia development, though the magnitude of risk varies:
- Early-onset pre-eclampsia: PAPP-A shows the strongest predictive value (mean difference -0.24 MoM) 1
- Late-onset pre-eclampsia: Moderate association (mean difference -0.15 MoM) 1
- Overall pre-eclampsia risk: Women with PAPP-A ≤0.4 MoM have 2.3% incidence versus 0.2% in those with normal PAPP-A 2
The predictive performance improves dramatically when PAPP-A is combined with other factors 3:
- PAPP-A + elevated BMI (≥35): 20-fold increased risk
- PAPP-A + elevated MAP: 115-fold increased risk (adjusted OR: 114.83)
- Each 1-point decrease in PAPP-A corresponds to an 84% increase in early-onset pre-eclampsia likelihood 3
Recent high-quality data from 2025-2026 demonstrates that PAPP-A cut-off of 0.65 MoM shows high sensitivity and specificity for predicting pre-eclampsia, especially when associated with IUGR (AUC 0.909) 4.
Prophylactic Management
Low-dose aspirin is the evidence-based intervention endorsed by ACOG and USPSTF 5, 6:
- Dose: 81 mg daily
- Timing: Initiate between 12-16 weeks of gestation (ideally before 16 weeks)
- Duration: Continue until delivery
- Mechanism: Inhibits cyclooxygenase-1, reducing thromboxane A2 production and improving placental perfusion 5
The 2016 ACOG guideline specifically recommends aspirin for high-risk factors including chronic hypertension, diabetes, renal disease, autoimmune disease, history of pre-eclampsia, and multifetal gestation 5. While low PAPP-A alone is not explicitly listed as a standalone indication, the combination of low PAPP-A with other moderate risk factors strengthens the recommendation 6.
Important Caveats
Isolated low PAPP-A has limitations: In truly low-risk nulliparous populations, PAPP-A <0.4 MoM alone shows poor positive predictive value (6.3% for pre-eclampsia) and should not be used as the sole criterion for aspirin initiation 7. However, this study's limitation is that it excluded women with pre-existing risk factors.
The key is risk stratification: Low PAPP-A should trigger assessment for additional risk factors (elevated BMI, elevated MAP, chronic hypertension, diabetes, prior pre-eclampsia) 3. When combined with these factors, the predictive value becomes clinically actionable.
Monitoring Approach
For women with low PAPP-A:
- Measure mean arterial pressure and BMI at first prenatal visit
- Assess for chronic medical conditions (hypertension, diabetes, renal disease, autoimmune disease)
- If PAPP-A <0.4-0.65 MoM plus any additional risk factor → initiate aspirin
- Consider second-trimester placental thickness assessment, which adds predictive value when combined with low PAPP-A 4
- Increased surveillance for pre-eclampsia symptoms, particularly between 28-34 weeks when detection rates peak 4
The evidence strongly supports that low PAPP-A is not merely a marker but identifies a pathophysiologic process of poor placentation that aspirin can partially ameliorate 5, 6. The combination approach maximizes detection while avoiding overtreatment of truly low-risk women.